To enhance the understanding of the diagnostic and therapeutic challenges of porocarcinoma (PC) and evaluate the efficacy of combination therapy with an anti-PD-1 monoclonal antibody and chemotherapy, highlighting its significance in the context of existing literature.
Key Findings:
Initial treatment with penpulimab and nab-paclitaxel resulted in a partial response after 2 cycles.
The patient experienced stable disease after 4 cycles but progressed after 5 cycles.
Combination therapy showed therapeutic efficacy in a rare malignancy, although resistance developed, ultimately leading to the patient's demise.
Interpretation:
The case suggests that combination therapy with anti-PD-1 monoclonal antibodies and chemotherapy may be a viable option for treating refractory porocarcinoma, despite the eventual development of resistance, indicating a need for further research.
Limitations:
The rarity of porocarcinoma limits the generalizability of findings.
The patient's multiple comorbidities may have influenced treatment outcomes.
Lack of long-term follow-up data limits the understanding of treatment efficacy.
Conclusion:
This case highlights the potential of immune checkpoint inhibitors in treating porocarcinoma and underscores the need for further research to establish effective treatment protocols and validate these findings.
